11/25
07:46 am
rckt
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
Low
Report
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
11/25
07:00 am
rckt
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
11/18
01:13 pm
rckt
Rocket Pharmaceuticals (NASDAQ:RCKT) had its price target lowered by analysts at Bank of America Corporation from $10.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Rocket Pharmaceuticals (NASDAQ:RCKT) had its price target lowered by analysts at Bank of America Corporation from $10.00 to $8.00. They now have a "buy" rating on the stock.
11/18
10:20 am
rckt
Rocket Pharmaceuticals (NASDAQ:RCKT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
Low
Report
Rocket Pharmaceuticals (NASDAQ:RCKT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
11/7
11:30 pm
rckt
Rocket Pharmaceuticals (NASDAQ:RCKT) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $16.00 price target on the stock.
Low
Report
Rocket Pharmaceuticals (NASDAQ:RCKT) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $16.00 price target on the stock.
11/6
04:28 pm
rckt
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress [Yahoo! Finance]
Medium
Report
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress [Yahoo! Finance]
11/6
04:00 pm
rckt
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Low
Report
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
10/26
06:47 am
rckt
Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now? [Yahoo! Finance]
Low
Report
Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now? [Yahoo! Finance]
10/23
06:03 pm
rckt
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/14
02:20 pm
rckt
Rocket Pharmaceuticals (NASDAQ:RCKT) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.
Low
Report
Rocket Pharmaceuticals (NASDAQ:RCKT) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.
10/14
07:32 am
rckt
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) [Yahoo! Finance]
Medium
Report
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) [Yahoo! Finance]
10/14
07:00 am
rckt
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
High
Report
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
10/10
04:08 pm
rckt
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/10
04:00 pm
rckt
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/3
11:37 am
rckt
Rocket Pharmaceuticals (NASDAQ:RCKT) had its price target lowered by analysts at Leerink Partners from $9.00 to $7.00. They now have a "market perform" rating on the stock.
Low
Report
Rocket Pharmaceuticals (NASDAQ:RCKT) had its price target lowered by analysts at Leerink Partners from $9.00 to $7.00. They now have a "market perform" rating on the stock.
9/19
01:30 pm
rckt
Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm